ARGININE ASPARTATE-CONTAINING COMPOSITION FOR SUPPRESSING OLD PERSON SMELL

Abstract

The present invention relates to a composition comprising arginine aspartate. The composition according to the present invention not only reduces 2-nonenal, but also inhibits the expression of MMP-1, has a collagen synthesis ability, reduces the expression of TNF-α, and inhibits the activity of tyrosinase. Therefore, the composition according to the present invention can be effectively used for suppressing senile body odor, alleviating wrinkles, anti-inflammation or whitening.

Claims

1. A composition for suppressing senile body odor, alleviating wrinkles, anti-inflammation, or whitening, comprising arginine aspartate.

2. The composition for suppressing senile body odor, alleviating wrinkles, anti-inflammation, or whitening according to claim 1, wherein the arginine aspartate is represented by the following formula (I): ##STR00002##

3. The composition for suppressing senile body odor according to claim 1, wherein the composition reduces 2-nonenal.

4. The composition according to claim 1, which is a cosmetic composition, pharmaceutical composition, or a foodstuff.

5. The composition according to claim 4, wherein the arginine aspartate is represented by the following formula (I): ##STR00003##

6. The composition according to claim 4, wherein the composition reduces 2-nonenal.

7. The composition according to claim 4, wherein the composition is a foodstuff.

8. The composition according to claim 4, wherein the composition is a cosmetic topical composition.

9. The composition according to claim 4, wherein the composition is a pharmaceutical composition.

10. A method for suppressing senile body odor, alleviating wrinkles, anti-inflammation, or whitening skin of a subject, comprising administering a composition comprising arginine aspartate to the subject.

11. The method according to claim 10, wherein the arginine aspartate is represented by the following formula (I): ##STR00004##

12. The method according to claim 10, wherein the composition reduces 2-nonenal.

13. The method according to claim 10, wherein the composition is a cosmetic composition, pharmaceutical composition, or a foodstuff.

14. A method for reducing 2-nonenal level or suppressing 2-nonenal production in a subject, comprising administering a composition comprising arginine aspartate to the subject.

15. The method according to claim 14, wherein the arginine aspartate is represented by the following formula (I): ##STR00005##

16. The method according to claim 14, wherein the composition is a cosmetic composition, pharmaceutical composition, or a foodstuff.

Description

BRIEF DESCRIPTION OF FIGURES

[0035] FIG. 1 is a graph showing the evaluation results of the ability of the arginine aspartate to remove 2-nonenal.

BEST MODE

[0036] The present invention will be described in more detail by following examples. It will be obvious to those skilled in the art that these examples are merely described for illustration of the present invention and the scope of the present invention is not limited thereto.

Example 1: Evaluation of the Removal of 2-Nonenal by Arginine Aspartate

[0037] The ability of the arginine aspartate of Formula (I) according to the present invention to remove 2-nonenal was evaluated.

[0038] 2-Nonenal was dissolved at a concentration of 0.1 wt % (1000 ppm) in 50 wt % ethanol aqueous solution containing 0.5 wt % Tween 80. Arginine aspartate was dissolved at a concentration of 5 wt % (50000 ppm) in a 50 wt % ethanol aqueous solution containing 0.5 wt % Tween 80.

[0039] The two solutions were mixed in a 1:1 ratio by weight to make a mixed solution. The mixed solution was left at room temperature and the change in the amount of 2-nonenal was analyzed by HPLC over time. That is, the change in the amount of 2-nonenal over time was analyzed by treating 0.05 wt % 2-nonenal with arginine aspartate at a concentration of 2.5 wt %.

[0040] Further, the 2-nonenal solution prepared above was diluted two-fold with a 50 wt % ethanol aqueous solution containing 0.5 wt % Tween 80 and the diluted solution was left at room temperature to analyze the change in the amount of 2-nonenal over time by HPLC. That is, the change in the amount of 2-nonenal over time was analyzed in a condition of 0.05 wt % of 2-nonenal untreated with arginine aspartate.

[0041] The results are shown in FIG. 1.

[0042] From FIG. 1, it was confirmed that when 2-nonenal, the causative material of body odor, was treated with arginine aspartate, the amount of 2-nonenal decreased by 74% after 20 hours, leaving only 26% by weight compared to the initial 100% by weight. On the other hand, it was confirmed that when 2-nonenal was not treated with arginine aspartate, there was no change in the amount of 2-nonenal.

Example 2: Evaluation of the Ability of the Arginine Aspartate to Inhibit MMP-1

[0043] Human skin fibroblasts were cultured at a concentration of 1×10.sup.4/well. The cells were treated with arginine aspartate for each concentration, and the MMP-1 expression level was measured using a PCR device to evaluate the ability of arginine aspartate to inhibit MMP-1. A group in which the cells were not treated with the sample was used as a control group (CON), and a group in which the cells were treated with 50 ppm of adenosine was used as a positive control group. The results are shown in Table 1.

TABLE-US-00001 TABLE 1 MMP-1 gene expression level (% of control) Concentration (ppm) CON 10 20 40 Arginine aspartate 100 86.7 82.2 76.6 Adenosine (50 ppm) 73.9

[0044] From Table 1, it was confirmed that 40 ppm of arginine aspartate had inhibitory effect of 23.4% on MMP-1, which was similar to the MMP-1 inhibitory effect at the 50 ppm concentration of adenosine, a positive control.

Example 3: Evaluation of Collagen Synthesis Ability

[0045] Human skin fibroblasts were cultured at a concentration of 1×10.sup.4/well. The cells were treated with each sample, and the amount of synthesized collagen was measured to evaluate the collagen synthesis ability. The cells were treated with adenosine at a concentration of 50 ppm as a positive control and arginine aspartate at a concentration of 10, 20 and 40 ppm. Collagen quantification was performed using a Type I Procollagen C-Peptide EIA kit (Takara, Japan). A group in which the cells were not treated with sample was used as a control group (CON). The results are shown in Table 2.

TABLE-US-00002 TABLE 2 Procollagen gene expression level (% of control) Concentration (ppm) CON 10 20 40 Arginine aspartate 100.0 123.6 133.0 136.8 Adenosine (50 ppm) 142.2

[0046] From Table 2, it was confirmed that the arginine aspartate according to the present invention exhibited an increase in collagen synthesis compared to the control group (CON). In particular, the arginine aspartate at a concentration of 40 ppm exhibited an increase in collagen synthesis similar to the case of treatment with adenosine, a positive control, at a concentration of 50 ppm.

Example 4: Evaluation of Anti-Inflammatory Effect

[0047] HaCaT cells were seeded in a 12-well plate by 1×10.sup.5 cells/well, and after 24 hours, they were replaced with a basal medium and starvated for 6 hours. After that, the medium was replaced with the basal medium containing the sample and the cells were incubated for 24 hours. After removal of the medium, UVB stimulation was applied, and the basal medium was added and the cells were cultured for 24 hours. The medium was completely removed and the cells were washed twice with PBS. The cells were disrupted using TRIsure to recover RNA, and then RT-PCR was performed to amplify TNF-α. Electrophoresis was performed on an agarose gel and the expression rate was measured using the Gel Documentation system. 200 μM dexamethasone was used as a positive control. The results are shown in Table 3.

TABLE-US-00003 TABLE 3 TNF-α gene expression level (% of control) Concentration (ppm) CON 10 20 40 Arginine aspartate 100.0 76.0 72.9 72.6 Dexamethasone (50 ppm) 66.9

[0048] From Table 3, it was confirmed that arginine aspartate at a concentration of 40 ppm exhibited decrease of 37.4% in TNF-α expression level, which was similar to the TNF-α expression inhibitory effect at 200 μL dexamethasone, a positive control.

Example 5: Evaluation of Whitening Effect

[0049] After adding 200 μL of 0.1M phosphate buffer (pH 6.8) to the Eppen tube, 20 μL of each sample solution diluted at each concentration was added. Then, 20 μL of mushroom tyrosinase (2,000 units/μL) and 200 μL of 0.3% tyrosine were added in order, and then reacted at 37° C. for 10 minutes. After 200 μL of this solution was transferred to a 96-well plate, absorbance was measured at 490 nm using an ELISA reader. 100 ppm arbutin was used as a positive control. The results are shown in Table 4.

TABLE-US-00004 TABLE 4 Tyrosinase activity (% of control) Concentration (ppm) CON 10 100 Arginine aspartate 100.0 72.5 71.7 Arbutin (100 ppm) 93.6 76.7

[0050] From Table 4, it was confirmed that arginine aspartate at a concentration of 100 ppm exhibited inhibition of 28.3% in tyrosinase activity, which was similar to the tyrosinase activity inhibitory effect at 100 ppm arbutin, a positive control.